iRhythm Technologies (IRTC) Projected to Post Quarterly Earnings on Thursday

iRhythm Technologies (NASDAQ:IRTC) will likely be posting its Q4 2025 results after the market closes on Thursday, February 19th. Analysts expect iRhythm Technologies to post earnings of $0.02 per share and revenue of $202.6060 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, February 19, 2026 at 4:30 PM ET.

iRhythm Technologies Stock Performance

IRTC stock opened at $148.32 on Wednesday. The stock’s 50 day simple moving average is $165.58 and its 200 day simple moving average is $171.60. iRhythm Technologies has a 12-month low of $92.52 and a 12-month high of $212.00. The firm has a market cap of $4.78 billion, a P/E ratio of -92.12 and a beta of 1.06. The company has a current ratio of 4.63, a quick ratio of 4.50 and a debt-to-equity ratio of 5.32.

Insider Buying and Selling at iRhythm Technologies

In related news, insider Patrick Michael Murphy sold 2,478 shares of the company’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $184.83, for a total value of $458,008.74. Following the completion of the sale, the insider owned 53,281 shares of the company’s stock, valued at $9,847,927.23. This represents a 4.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Chad Patterson sold 280 shares of the firm’s stock in a transaction dated Tuesday, December 2nd. The shares were sold at an average price of $184.83, for a total transaction of $51,752.40. Following the transaction, the insider directly owned 43,387 shares in the company, valued at approximately $8,019,219.21. The trade was a 0.64% decrease in their position. The SEC filing for this sale provides additional information. 0.68% of the stock is owned by insiders.

Institutional Trading of iRhythm Technologies

A number of institutional investors have recently made changes to their positions in IRTC. Arrowstreet Capital Limited Partnership increased its stake in shares of iRhythm Technologies by 6,415.4% during the third quarter. Arrowstreet Capital Limited Partnership now owns 541,039 shares of the company’s stock valued at $93,053,000 after acquiring an additional 532,735 shares during the period. Polar Capital Holdings Plc increased its position in shares of iRhythm Technologies by 24,782.1% during the 3rd quarter. Polar Capital Holdings Plc now owns 335,908 shares of the company’s stock valued at $57,773,000 after purchasing an additional 334,558 shares during the period. Holocene Advisors LP raised its stake in shares of iRhythm Technologies by 2,023.1% in the 2nd quarter. Holocene Advisors LP now owns 313,094 shares of the company’s stock worth $48,204,000 after buying an additional 298,347 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of iRhythm Technologies by 45.6% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 829,862 shares of the company’s stock valued at $147,251,000 after buying an additional 259,800 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its stake in iRhythm Technologies by 47.8% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 502,120 shares of the company’s stock valued at $89,098,000 after buying an additional 162,479 shares in the last quarter.

Analyst Ratings Changes

A number of brokerages have weighed in on IRTC. Needham & Company LLC reissued a “buy” rating and set a $244.00 target price on shares of iRhythm Technologies in a report on Monday, January 12th. Truist Financial lowered their price objective on shares of iRhythm Technologies from $230.00 to $215.00 and set a “buy” rating for the company in a research report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of iRhythm Technologies in a research note on Thursday, January 22nd. Canaccord Genuity Group lifted their target price on iRhythm Technologies from $193.00 to $212.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of iRhythm Technologies in a report on Monday, January 12th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, iRhythm Technologies presently has a consensus rating of “Moderate Buy” and a consensus target price of $219.23.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.